Comparison of effects of Albumin-bound paclitaxel and Paclitaxel combined with Lobaplatin in treatment of patients with advanced cervical cancer
Objective:To compare effects of Albumin-bound paclitaxel and Paclitaxel combined with Lobaplatin in treatment of patients with advanced cervical cancer.Methods:A prospective study was conducted on 78 patients with advanced cervical cancer admitted to this hospital from February 2021 to February 2023.According to the random number table method,they were divided into study group and control group,39 cases in each group.The control group was treated with Paclitaxel combined with Lobaplatin,while the study group was treated with Albumin-bound paclitaxel combined with Lobaplatin.The clinical efficacy,the vascular endothelial growth factor(VEGF)levels,the tumor markers[cytoplasmic thymidine kinase 1(TK1),squamous cell carcinoma antigen(SCC),cyto-keratin 19 fragment antigen 21-1(CYFRA21-1)]levels,the quality of life[Karnofsky performance status(KPS)]score before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The objective remission rate of the study group was 94.87%(37/39),which was higher than 79.49%(31/39)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the VEGF levels of the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of TK1,SCC and CYFRA21-1 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the KPS scores of the two groups were higher than those before the treatment,that in the study group was higher than that in the control group,and the differences were statistically significant(P<0.05).Further,the incidence of adverse reactions in the study group was 10.26%(4/39),which was lower than 28.21%(11/39)in the control group,and the differences were statistically significant(P<0.05).Conclusions:Albumin-bound paclitaxel combined with Lobaplatin in the treatment of the patients with advanced cervical cancer can improve the objective remission rate and the quality of life scores,and reduce the levels of serum tumor markers,VEGF and the incidence of adverse reactions.Moreover,it is superior to Paclitaxel combined with Lobaplatin treatment.
Albumin-bound paclitaxelLobaplatinCervical cancerTumor markerVascular endothelial growth factorQuality of lifeAdverse reaction
万方数据
维普
